JAM3 and infection: We observed consistent performance of PAX1 and JAM3 methylation in screening hrHPV-positive patients with CIN2+ regardless of HPV16/18 or non-16/18 hrHPV infections, and PAX1/JAM3 methylation levels were comparable between high-grade cervical lesions caused by non-16/18 hrHPV and HPV16/18.